Do SSRIs cause gynaecomastia? This is a clinically important question for the many men prescribed selective serotonin reuptake inhibitors in the UK. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is listed as a rare or uncommon adverse reaction in the Summary of Product Characteristics for several SSRIs. The proposed mechanism involves serotonin's influence on prolactin secretion, though definitive large-scale evidence is lacking. This article explores the evidence, identifies which SSRIs have been most frequently implicated, and outlines what to do if you notice breast changes whilst taking an antidepressant.

Can SSRIs Cause Gynaecomastia?

SSRIs can rarely cause gynaecomastia, plausibly via serotonin-driven hyperprolactinaemia disrupting the oestrogen-testosterone balance, though robust large-scale evidence is lacking and most reports come from individual case reports.

Selective serotonin reuptake inhibitors (SSRIs) are among the most widely prescribed antidepressants in the UK, used to treat conditions including depression, anxiety disorders, and obsessive-compulsive disorder. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised, though relatively uncommon, side effect associated with certain medications. The question of whether SSRIs directly cause gynaecomastia is nuanced, and the evidence base remains limited.

It is important to distinguish true gynaecomastia (proliferation of glandular breast tissue) from pseudogynaecomastia (fatty tissue deposition without glandular involvement), as the two have different causes and management pathways. Rarely, new breast changes in males may represent male breast cancer, which — although uncommon — must be considered during clinical assessment.

SSRIs work primarily by blocking the reuptake of serotonin in the brain, increasing its availability in synaptic clefts. Serotonin also plays a role in modulating prolactin secretion from the pituitary gland, and it has been proposed — though not conclusively established — that elevated prolactin levels (hyperprolactinaemia) may disrupt the balance between oestrogen and testosterone, potentially stimulating breast tissue growth. This mechanistic explanation is biologically plausible but should be regarded as a hypothesis rather than a proven causal pathway. Some SSRIs have also been associated with galactorrhoea (nipple discharge) in case reports and some Summary of Product Characteristics (SmPCs), consistent with a prolactin-mediated effect.

There is no definitive, large-scale clinical evidence firmly establishing SSRIs as a primary cause of gynaecomastia. Most reported cases appear in individual case reports or small case series rather than robust randomised controlled trials. UK SmPCs for individual SSRIs list gynaecomastia as an adverse reaction with varying frequency categories — often classified as 'rare' or 'not known' — and the frequency designation differs between products. Clinicians and patients should consult the relevant SmPC on the Electronic Medicines Compendium (emc) for product-specific information.

Other contributing factors — such as age, body weight, alcohol use, recreational drug use, and concurrent medications — must always be considered when evaluating breast tissue changes in a patient taking an SSRI. A thorough clinical assessment is essential before attributing gynaecomastia solely to antidepressant therapy.

If you suspect your SSRI or any other medicine is causing a side effect, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Which SSRIs Are Most Commonly Linked to Breast Tissue Changes?

Paroxetine appears most frequently in case reports of SSRI-related gynaecomastia, though robust comparative risk data between individual SSRIs are lacking and polypharmacy often complicates attribution.

Whilst all SSRIs share a broadly similar mechanism of action, individual agents differ in their pharmacological profiles and receptor affinities. However, robust comparative data on the relative risk of gynaecomastia between individual SSRIs are lacking, and any apparent differences in reported frequency should be interpreted cautiously, as they may reflect prescribing patterns, reporting bias, or differences in patient populations rather than true pharmacological differences.

Sertraline and fluoxetine are among the most frequently prescribed SSRIs in the UK, and isolated case reports have linked both to gynaecomastia, though the absolute risk appears low. Paroxetine appears more frequently in case reports of drug-induced gynaecomastia; some have suggested this may relate to its pharmacological profile, though the evidence is based largely on spontaneous reports and case series rather than comparative clinical studies. Citalopram and escitalopram have also been implicated in rare cases. Clinicians should consult the individual UK SmPC for each agent (available via the emc) for the most accurate and up-to-date adverse reaction information, including frequency categories.

It is important to note that SSRIs are sometimes prescribed alongside other medications that independently carry a well-established risk of gynaecomastia. These include spironolactone, cimetidine and other H2-receptor antagonists, finasteride and dutasteride, anti-androgens, anabolic steroids, ketoconazole, and certain antiretrovirals. Antipsychotics are potent dopamine antagonists that significantly raise prolactin and are far more strongly associated with gynaecomastia than SSRIs. In cases of polypharmacy, identifying the causative agent can be clinically challenging, and a systematic medication review — including consideration of dechallenge and rechallenge where clinically appropriate — may be required.

Key points to consider include:

• Evidence linking individual SSRIs to gynaecomastia is largely based on case reports and spontaneous pharmacovigilance reports; no robust risk ranking between agents is currently possible

• Polypharmacy complicates attribution of breast changes to any single drug; well-established causes such as spironolactone, finasteride/dutasteride, and anti-androgens should be reviewed

• The duration of treatment and individual patient factors (e.g., hepatic function, hormonal status) influence overall risk

• Spontaneous resolution has been reported in some cases following dose reduction or discontinuation

• Frequency categories in SmPCs vary by product and are often listed as 'rare' or 'not known'

Healthcare professionals should review the full medication list when a patient presents with new-onset gynaecomastia, and consult the BNF and relevant SmPCs for current adverse-effect and caution information.

What to Do If You Notice Breast Swelling While Taking an SSRI

Contact your GP promptly if you develop breast swelling, a lump, or nipple discharge whilst taking an SSRI; do not stop the medication without medical advice, as discontinuation syndrome and mental health deterioration are risks.

Noticing any change in breast tissue can understandably cause concern. If you are taking an SSRI and develop breast swelling, tenderness, or the appearance of a lump, it is important to seek a medical assessment promptly — not because the change is necessarily serious, but because it warrants proper evaluation to identify the cause and rule out other conditions, including the rare possibility of male breast cancer.

You should contact your GP if you experience:

• Unilateral or bilateral breast swelling or tenderness

• A palpable lump beneath the nipple or areola

• Nipple discharge (including galactorrhoea)

• Breast pain that is persistent or worsening

• Any breast change that causes you concern

Seek urgent assessment if you notice any of the following features, which may warrant referral via the suspected cancer pathway (in line with NICE NG12: Suspected Cancer: Recognition and Referral):

• A hard, irregular, or rapidly enlarging breast lump

• Skin changes over the breast (e.g., puckering, dimpling, or ulceration)

• Unilateral nipple changes, particularly in men aged 50 or over

• Unexplained breast lump in a man aged 30 or over

Your GP will take a thorough history, including your full medication list, duration of SSRI use, and other relevant factors such as alcohol intake or family history. Blood tests may be arranged to check hormone levels, including testosterone, oestradiol, luteinising hormone (LH), follicle-stimulating hormone (FSH), prolactin, and human chorionic gonadotrophin (hCG), as well as thyroid and liver function. Where a testicular or hCG-secreting tumour is suspected, a testicular examination and, if indicated, testicular ultrasound should be performed. These investigations are consistent with the assessment approach outlined in NICE CKS: Gynaecomastia.

Further investigation such as breast ultrasound or referral to a breast clinic may be recommended depending on clinical findings. Referral via the two-week suspected cancer pathway should be arranged where NICE NG12 criteria are met.

Do not stop taking your SSRI without first speaking to your GP or prescriber. Abruptly discontinuing antidepressant therapy can cause discontinuation syndrome and may worsen the underlying mental health condition being treated. If your mental health deteriorates at any point, seek advice promptly. Your doctor can assess whether a dose adjustment, a switch to an alternative agent, or watchful waiting is the most appropriate course of action. In many cases, gynaecomastia associated with medication is reversible once the causative drug is reduced or changed, though resolution may take several months.

If you believe your SSRI or any other medicine has caused a side effect, please report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Alternative Treatments If SSRIs Are Causing Side Effects

Alternative antidepressants such as mirtazapine or SNRIs, and evidence-based psychological therapies such as CBT, may be considered if an SSRI is suspected to be causing gynaecomastia, guided by a prescriber and relevant NICE guidance.

If an SSRI is suspected to be contributing to gynaecomastia or other troublesome side effects, there are several evidence-based alternatives that your prescriber may consider. The decision to switch or adjust treatment should always be made collaboratively, weighing the benefits of the current therapy against the impact of side effects on quality of life.

Experiencing these side effects? Our pharmacists can help you navigate them →

Alternative antidepressant classes that may be considered include:

• SNRIs (serotonin-noradrenaline reuptake inhibitors) such as venlafaxine or duloxetine — these have a different receptor profile, though it should be noted that venlafaxine has rare reports of hyperprolactinaemia and galactorrhoea in its SmPC. Evidence specifically comparing SNRI and SSRI risk of gynaecomastia is limited, and any switch should be guided by the individual's clinical profile and the BNF/SmPC for the chosen agent.

• Mirtazapine — a noradrenergic and specific serotonergic antidepressant (NaSSA) with a distinct mechanism; it is less commonly associated with hormonal side effects, though it carries its own side effect profile including weight gain and sedation.

• Agomelatine — a melatonin receptor agonist licensed in the UK for major depressive disorder with a different hormonal impact profile. However, it requires regular liver function monitoring (at initiation, and at weeks 3, 6, 12, and 24 of treatment), is contraindicated in hepatic impairment, and its availability may depend on local formulary approval. It is not recommended by NICE as a routine first-line option, and prescribing should follow local guidance.

• Bupropion — not licensed in the UK for the treatment of depression (it is licensed for smoking cessation). It may occasionally be considered in specialist settings on an off-label basis, and any such use should be initiated and supervised by a specialist.

In cases where psychological therapies are appropriate, NICE NG222 (Depression in Adults: Treatment and Management) recommends cognitive behavioural therapy (CBT) and other evidence-based psychological interventions as effective first-line or adjunctive treatments for depression. NICE CG113 provides equivalent guidance for generalised anxiety disorder and panic disorder. These approaches may reduce reliance on pharmacotherapy in suitable patients.

For patients in whom gynaecomastia persists despite medication changes, referral to an endocrinologist or breast surgeon may be appropriate. Surgical intervention (subcutaneous mastectomy) is occasionally considered for persistent, symptomatic gynaecomastia that does not resolve with conservative management, in line with NICE CKS guidance on referral. All treatment decisions should be guided by a qualified healthcare professional and tailored to the individual patient's clinical needs and preferences.

Frequently Asked Questions